Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | TRPV1 | Q8NER1 | 9/20 | 0.52 |
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | GALR3 | O60755 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.49 |
| ▸ | RELA | Q04206 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10803341 | 0.85 | KDM4E (0.75) | KDM4ETRPV1NPC1RAB9AGALR3 | |
| SCHEMBL10112883 | 0.85 | KDM4E (0.75) | KDM4ETRPV1NPC1RAB9AGALR3 | |
| SCHEMBL10113149 | 0.82 | KDM4E (0.52) | KDM4ETRPV1NPC1RAB9AGALR3 | |
| SCHEMBL10113168 | 0.81 | NPC1 (0.58) | KDM4ETRPV1NPC1RAB9AGALR3 | |
| SCHEMBL13565466 | 0.80 | HPGD (0.43) | KDM4ENPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL13210620 | 0.79 | NPC1 (0.67) | KDM4ETRPV1NPC1RAB9AGALR3 | |
| SCHEMBL10113152 | 0.79 | KDM4E (0.65) | KDM4ETRPV1NPC1RAB9AGALR3 | |
| SCHEMBL10113143 | 0.78 | KDM4E (0.58) | KDM4ETRPV1NPC1RAB9AGALR3 | |
| SCHEMBL10116465 | 0.78 | KDM4E (0.63) | KDM4ETRPV1NPC1RAB9AGALR3 | |
| SCHEMBL10112986 | 0.77 | STING1 (0.56) | KDM4ETRPV1NPC1RAB9AGALR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8115027-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2012-02-14 | — | — | US | disclosed |
| US-8115027-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2012-02-14 | — | — | US | disclosed |
| US-20110039802-A1 | NPY Y5 ANTAGONIST | KAWANISHI YASUYUKI | 2011-02-17 | — | — | US | disclosed |
| US-20110039802-A1 | NPY Y5 ANTAGONIST | KAWANISHI YASUYUKI | 2011-02-17 | — | — | US | disclosed |
| US-20100292500-A1 | NPY Y5 ANTAGONIST | KAWANISHI YASUYUKI | 2010-11-18 | — | — | US | disclosed |
| US-20100292500-A1 | NPY Y5 ANTAGONIST | KAWANISHI YASUYUKI | 2010-11-18 | — | — | US | disclosed |
| US-7781461-B2 | NPY Y5 antagonist | KAWANISHI YASUYUKI | 2010-08-24 | — | — | US | disclosed |
| US-7781461-B2 | NPY Y5 antagonist | KAWANISHI YASUYUKI | 2010-08-24 | — | — | US | disclosed |
| US-7265130-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2007-09-04 | — | — | US | disclosed |
| US-7265130-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2007-09-04 | — | — | US | disclosed |
| US-20070015762-A1 | NPY Y5 antagonist | KAWANISHI YASUYUKI | 2007-01-18 | — | — | US | disclosed |
| US-20070015762-A1 | NPY Y5 antagonist | KAWANISHI YASUYUKI | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015762-A1 | NPY Y5 antagonist | NPY5R, NPY1R, NPY2R | KDM4E 1668/4885TRPV1 774/4885NPC1 1435/4885 |
| US-20100292500-A1 | NPY Y5 ANTAGONIST | NPY5R, NPY1R, NPY2R | KDM4E 1627/4885TRPV1 534/4885NPC1 1353/4885 |
| US-20110039802-A1 | NPY Y5 ANTAGONIST | NPY5R, NPY1R, NPY2R | KDM4E 1653/4885TRPV1 795/4885NPC1 1462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.